AAM
CRNX

Advisors Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Advisors Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Sell
3,933
-1,697
-30% -$63.1K ﹤0.01% 1214
2026
Q1 		$204K Sell
5,630
-939
-14% -$41.9K ﹤0.01% 1141
2025
Q4 		$306K Sell
6,569
-83
-1% -$3.69K 0.01% 1062
2025
Q3 		$277K Sell
6,652
-24
-0.4% -$767 ﹤0.01% 1079
2025
Q2 		$192K Buy
6,676
+2
+0% +$62 ﹤0.01% 1121
2025
Q1 		$224K Buy
6,674
+1,761
+36% +$65.8K ﹤0.01% 1088
2024
Q4 		$251K Buy
4,913
+2,107
+75% +$118K ﹤0.01% 1080
2024
Q3 		$143K Buy
2,806
+1,008
+56% +$52K ﹤0.01% 1165
2024
Q2 		$80.5K Buy
+1,798
New +$83K ﹤0.01% 1231

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Advisors Asset Management's CRNX Position: Q2 2026 in Review

Advisors Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 30% in Q2 2026, selling an estimated $63.1K and leaving 3,933 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #1214.

Advisors Asset Management first reported a position in CRNX in Q2 2024 and has held it in 9 quarters since. The position peaked at $306K in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Advisors Asset Management held 3,933 shares of Crinetics Pharmaceuticals worth $147K as of Q2 2026.
  • Advisors Asset Management sold 1,697 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $63.1K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Advisors Asset Management's portfolio in Q2 2026, its #1214 holding.
  • Advisors Asset Management first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Advisors Asset Management's Crinetics Pharmaceuticals position peaked at $306K in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.